Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Asrin: Dosage Form: Qurs (Tablet),
Dosage: Two Tablets (500 mg each) twice a day after meals,
Route of Administration: Oral,
Composition: 1. Bekh-e-Asrol (Rauwolfia serpentina) 2.5 K
Sponsors
National Research Institute of Unani Medicine for Skin Disorders.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Participants of any sex aged 35-65 years 2. Stage-I Hypertension according to JNC 7 (Systolic BP 140-159 & Diastolic BP 90-99 mmHg) 3. Participants willing to sign the informed consent form and to comply with the protocol
Exclusion criteria
Exclusion criteria: 1. Participants aged 65 years 2. Participants with SBP >=160 mmHg and DBP >=100 mmHg 3. Participants with Secondary Hypertension and Type 2 DM 4. Known cases of significant Pulmonary/Cardiovascular/ Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc. 5. Pregnancy and Lactation 6. Known allergy, sensitivity or intolerance to the study drug or any of its ingredients 7. Any other clinical condition that in the opinion of the investigator would compromise the patientâ??s safety or successful participation in the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in SBP â?¥ 20 mmHg and diastolic blood pressure â?¥ 10 mmHg from baseline.Timepoint: 4 Weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Systemic safety assessmentTimepoint: 4 Weeks | — |
Countries
India
Contacts
Public ContactDr Mohammad Mubashshir Arfee
National Research Institute of Unani Medicine for Skin Disorders.
Outcome results
None listed